Therapeutic Response

BRAF p.V600E status confers therapeutic sensitivity to Dabrafenib in patients with Melanoma.

Statements

Source and description
Tafinlar (dabrafenib) [product monograph]. HC. Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Tafinlar (dabrafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.